Mouse models of human AML accurately predict chemotherapy response

Genes Dev. 2009 Apr 1;23(7):877-89. doi: 10.1101/gad.1771409.


The genetic heterogeneity of cancer influences the trajectory of tumor progression and may underlie clinical variation in therapy response. To model such heterogeneity, we produced genetically and pathologically accurate mouse models of common forms of human acute myeloid leukemia (AML) and developed methods to mimic standard induction chemotherapy and efficiently monitor therapy response. We see that murine AMLs harboring two common human AML genotypes show remarkably diverse responses to conventional therapy that mirror clinical experience. Specifically, murine leukemias expressing the AML1/ETO fusion oncoprotein, associated with a favorable prognosis in patients, show a dramatic response to induction chemotherapy owing to robust activation of the p53 tumor suppressor network. Conversely, murine leukemias expressing MLL fusion proteins, associated with a dismal prognosis in patients, are drug-resistant due to an attenuated p53 response. Our studies highlight the importance of genetic information in guiding the treatment of human AML, functionally establish the p53 network as a central determinant of chemotherapy response in AML, and demonstrate that genetically engineered mouse models of human cancer can accurately predict therapy response in patients.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use*
  • Core Binding Factor Alpha 2 Subunit / genetics
  • Disease Models, Animal*
  • Gene Expression Profiling
  • Gene Expression Regulation, Neoplastic
  • Genes, ras / genetics
  • Genes, ras / physiology
  • Genotype
  • Humans
  • Kaplan-Meier Estimate
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / genetics*
  • Leukemia, Myeloid, Acute / pathology
  • Leukemia, Myeloid, Acute / physiopathology
  • Mice
  • Mice, Inbred C57BL*
  • Myeloid-Lymphoid Leukemia Protein / genetics
  • Oncogene Proteins, Fusion / genetics
  • Prognosis
  • RUNX1 Translocation Partner 1 Protein
  • Tumor Suppressor Protein p53 / genetics


  • AML1-ETO fusion protein, human
  • Antineoplastic Agents
  • Core Binding Factor Alpha 2 Subunit
  • MLL-ENL oncoprotein, human
  • Oncogene Proteins, Fusion
  • RUNX1 Translocation Partner 1 Protein
  • Tumor Suppressor Protein p53
  • Myeloid-Lymphoid Leukemia Protein